NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.…
NRx (NRXP) Q3 2026 Earnings Call Transcript
NRx Pharmaceuticals (NASDAQ: NRXP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 29 employees.
The shares were at 2.150 USD on 20 November 2026, down 19.5% over 52 weeks. Its 52-week range is 1.620 USD to 5.055 USD: the price is 57.5% below the high and 32.7% above the low.
Its market capitalisation is 95.31M USD.
NRx Pharmaceuticals reports return on equity of 179.6% and revenue up 378.9% year over year.
It holds more cash than debt, a net cash position of 18.84M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. The next earnings report is expected on 24 March 2027.